We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis
Effectiveness and safety of 11 doses of SGLT2 inhibitors in type 2 diabetes patients not well controlled with metformin
AI simplified
Abstract
23 randomized controlled trials involving 9144 patients assessed efficacy and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2is) as add-on therapy to metformin in type 2 diabetes mellitus.
- Most SGLT2is reduced glycated hemoglobin () by 0.45% to 0.80%, fasting plasma glucose (FPG) by 0.78 to 2.02 mmol/L, and body weight by 0.88 to 2.67 kg compared to placebo.
- 10 mg of henagliflozin increased the incidence of adverse events, while none of the interventions increased risks of serious adverse events or urinary tract infections.
- 50 mg of empagliflozin was associated with higher risks of hypoglycemia, and 10 mg of empagliflozin increased the risk of genital infections.
- 15 mg of ertugliflozin showed optimal efficacy for HbA1c reduction, while 300 mg of canagliflozin was the best option for FPG reduction and weight loss.
- Results suggest some novel SGLT2is may have promising efficacy and safety profiles, but further research is needed to confirm these findings.
AI simplified
Key numbers
-0.80%
Reduction
Reduction observed with 10 mg of henagliflozin.
-2.02 mmol/L
FPG Reduction
Highest reduction among interventions compared to placebo.
-2.67 kg
Weight Loss
Notable reduction associated with 300 mg of canagliflozin.